ArticleMicroorganisms2023
Performance of the Disc Diffusion Method, MTS Gradient Tests and Two Commercially Available Microdilution Tests for the Determination of Cefiderocol Susceptibility in
Article in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- In Vitro Activity of Cefiderocol, Eravacycline, and Imipenem-Relebactam Against Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- The Achilles' heel of the Trojan Horse? A systematic evaluation of cefiderocol susceptibility testing.The Journal of antimicrobial chemotherapy · 2025Article
- The impact of commercially available media on cefiderocol susceptibility testing by broth microdilution method.Journal of clinical microbiology · 2025Article
- Evaluating Antimicrobial Susceptibility Testing Methods for Cefiderocol: A Review and Expert Opinion on Current Practices and Future Directions.Antibiotics (Basel, Switzerland) · 2025Review
- Cefiderocol Antimicrobial Susceptibility Testing by Disk Diffusion: Influence of Agar Media and Inhibition Zone Morphology inAntibiotics (Basel, Switzerland) · 2025Article
- Impact of media brand on cefiderocol disk diffusion results.Journal of clinical microbiology · 2025Article
- A multicenter performance evaluation of cefiderocol MIC results: ComASP in comparison to CLSI broth microdilution.Journal of clinical microbiology · 2025Article
- Issues with Cefiderocol Testing: Comparing Commercial Methods to Broth Microdilution in Iron-Depleted Medium-Analyses of the Performances, ATU, and Trailing Effect According to EUCAST Initial and Revised Interpretation Criteria.Diagnostics (Basel, Switzerland) · 2024Article
- Real-world performance of susceptibility testing for cefiderocol: insights from a prospective multicentre study on Gram-negative bacteria.JAC-antimicrobial resistance · 2024Article
- Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus.Annals of clinical microbiology and antimicrobials · 2024Article
- Challenges in the Detection of Polymyxin Resistance: From Today to the Future.Microorganisms · 2024Review
- Cefiderocol and Sulbactam-Durlobactam against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefiderocol is a siderophore-conjugated cephalosporin with potent activity against multidrug-resistant Gram-negative pathogens including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.